Vaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol Levels – ExecEdge
Now Reading:
Vaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol Levels
Full Article 50 second read

Vaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol Levels

By Daniella Parra

Vaxxinity, Inc. (Nasdaq: VAXX) said it demonstrated that VXX-401 lowers LDL cholesterol, supporting its potential for treating hypercholesterolemia.

The VXX-401, a synthetic peptide vaccine, aims to provide a safe and effective solution against heart disease by targeting PCSK9, the company said in a statement.

The studies were published in the Journal of Lipid Research, which show that VXX-401 induces a strong antibody response against PCSK9, resulting in a 44% LDL cholesterol reduction in cynomolgus monkeys, it said.

“Vaxxinity is committed to providing scalable, accessible, game-changing solution for worldwide heart health,” said Mei Mei Hu, CEO of Vaxxinity. “Despite multiple approved medications for LDL-C reduction, heart disease remains the number one killer in the world. A cholesterol vaccine like VXX-401 may provide a cost-effective and widely deployable solution that could potentially benefit hundreds of millions of people at risk.”

Contact:

Healthcare Edge

Editor@Executives-edge.com

Leave a Reply

Your email address will not be published. Required fields are marked *

Input your search keywords and press Enter.